Orexigen Obesity Drug Found to Reduce Food Intake
Posted on: Thursday, 25 October 2007, 06:00 CDT
Orexigen Therapeutics has announced positive results for a preclinical study of Contrave, which is one of its two late-stage obesity drug candidates. The drug was found to increase the firing of neurons associated with reduction in food intake and satiety.
Contrave employs a proprietary formulation of two CNS molecules, bupropion and naltrexone, that have been independently approved by the FDA in other indications. The unique combination of these molecules is designed to provide more clinically meaningful weight loss for patients by both initiating weight loss and sustaining it over a longer period of time.
The combination of bupropion and naltrexone, the components of Contrave, resulted in a 94% reduction of food intake in obese mice, greater than either drug alone. The combination directly increased firing of neurons associated with reduction in food intake and satiety. The drugs act in a part of the brain where food reward pathways are located. The interaction between bupropion and naltrexone appeared more potent in obese mice than in lean mice.
Michael Cowley, founder and chief scientific officer of Orexigen, said: "We originally theorized that the combination of bupropion and naltrexone, the components of Contrave, would stimulate proopiomelanocortin (POMC) neuronal firing which would lead to sustained weight loss. These new findings indicate that Contrave may also modulate food cravings through its effect on reward pathways. We believe this aspect of Contrave's mechanism of action may have the potential to differentiate it from other pharmaceutical therapies available or in development for the treatment of obesity."
Source: Datamonitor
Related Articles
- Increased Food Intake Alone Explains The Increase In Body Weight
- Do You Know Which Food Import & Export Agents Are Selling At A Loss And Whose Profit Margins Are Plummeting?
- Type 2 Diabetes Patients on Technosphere Insulin Exhibited No Adverse Effect on Pulmonary Function With Significant HbA1c Reductions, and Showed Significant Weight Reduction Compared to Injected Insulin Analog
- OREXIGEN(TM) Therapeutics Reports Positive Phase II Results for Contrave(TM) Combination-Therapy to Treat Obesity
- For Your Health: A Margarita and BLT: New Food Combinations and Modifications Seek to Boost Nutrition Levels
- Wellstone Filters Achieves Revenues and Significant Reduction of Net Loss In Fiscal 2006 First Quarter
- Largest Retrospective Study to Date Shows Reduction in Vision Loss for Stroke and TBI Patients Treated With NovaVision Therapy
- TissueLink Medical Announces Presentation of New Clinical Data Documenting Reduction in Blood Loss
- Nutrient Combination Stops Cancer Metastasis in Mice
- Processed Food Makers Resist Salt Reductions
 |
 |
User Comments (0)
RSS Feeds